DOCSLIB.ORG

ANAVEX 2-73, a Clinical Candidate for Neurodevelopmental Disorders: New Data Including An-Seizure Data in Angelman Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANAVEX 2-73, a Clinical Candidate for Neurodevelopmental Disorders: New Data Including An�-Seizure Data in Angelman Syndrome ANAVEX 2-73, a Clinical Candidate for Neurodevelopmental Disorders: New data Including AnC-Seizure data in Angelman Syndrome Christopher U Missling, PhD, President & CEO AEDD Trials XIV Conference May 2017 2 Sigma-1 Receptor AcCvaCon and NeurodegeneraCve Diseases 3 Sigma-1 Receptor AcCvaCon Related to AnC-Seizure Effects 4 Confirmed Effects of Sigma-1 Receptor AcCvaCon … ü Synaptogenesis ü Restores Ca2+ imbalance ü Reduces InflammaCon ü Reduces Oxidave stress ü Reduces Tau hyper-phosporylaon ü Restores Mitochondrial dysfuncion … effects relevant in both neurodevelopmental as well as neurodegenerave diseases 5 Sigma-1R Agonists MoA: Restoring Homeostasis ANAVEX 2-73 Sigma-1R helping / Restoring Homeostasis sCmulaCng own body to regain funcConality Su et al., Trends Pharmacol Sci. 2016 Villard et al., J. Psychopharmacol. 2011 [σ1 Antagonist] Source: Adapted from Miki et al, Dec 9. doi: 10.1111/neup.12080 Neuropathology 2013 6 Glembotski et al., Circulaon Research. 2007;101:975-984 ANAVEX™ 2-73 Shown to be Safe in Phase 2a Clinical Trial of Mild-to-Moderate Alzheimer’s PaCents § Phase 2a results demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile at doses between 10mg and 50mg of oral daily ANAVEX 2-73 § Primary endpoints met with favorable safety and tolerability § Secondary endpoints met with supporCve exploratory biomarker, cogniCon and funcCon measures correlaCng § Low-High dose was stascally significant to affect MMSE-Δ and EEG/ERP-Δ scores with MMSE-Δ (p=0.0285) and EEG/ERP-Δ (p=0.0168), respecvely 7 Angelman Syndrome § A rare neuro-genec disorder § Majority of cases due to mutaCons or deleCon of UBE3A gene (Chromosome 15) § Affects 1 in 15,000 Symptoms include: § Seizures (presented in over 80% of affected individuals) § Ataxia § CogniCve impairment § Speech impairment § Sleep disorders 8 Audiogenic Seizures in an Angelman Syndrome Model § ANAVEX 2-73 (10 mg/kg ip dosed daily for 14 days) was evaluated for audiogenic-induced seizures in 3-4 month old 129- background mice with mutaCon in Ube3a § The study was sponsored by FoundaCon for Angelman Syndrome. The work was carried out at the Anderson Lab at Baylor University in Houston, TX § Audiogenic seizures are hypothesized to model tonic-clonic seizures with brainstem origin − Audiogenic seizures are thought to best model temporal lobe epilepsy (TLE) and reflex seizures# # Kandratavicius L et al. Neuropsychiatr Dis Treat. 2014 Sep 9;10:1693-705 9 ParCal Rescue of Audiogenic Seizure with ANAVEX 2-73 § ANAVEX 2-73 administraCon significantly reduced audiogenic- induced seizures (p<0.01, KO vehicle vs. KO ANAVEX 2-73) p=0.0065 10 ANAVEX 2-73: Dose-Dependent AnC-Seizure Effects Significant Seizure Reducon with ANAVEX2-73 in Long-Lasng Effect Shown in both MES and PTZ-Induced Seizure Models PTZ-Induced Seizures p<0.001 p<0.001 100 100 90 90 80 MES-induced 80 convulsions # 70 70 60 60 50 50 4 hours PTZ-induced 40 40 6 hours convulsions 30 30 % of Seizure reducCon % of Seizure % of Seizure reducCon % of Seizure 20 20 10 10 0 0 Vehicle 10 mg/kg 30 mg/kg 100 mg/kg Vehicle 60 mg/kg (p.o.) (p.o.) (p.o.) (p.o.) ANAVEX 2-73 also shows synergisCc acvity with three generaCons of epilepsy drugs currently on the market: ETS (ZaronCn®), VPA (Depakene®) and Gabapenn (Neuronn®) Presented at AES Mee.ng 2015, # results have been confirmed by the ETSP screening program 11 ANAVEX 2-73 Significantly Reduces the Number of Spasms in a Pre-Treatment Experiment of InfanCle Spasms in Infant Rat Model 150 1 hour pre-treatment with r 100 p<0.001 ANAVEX 2-73 (30mg/kg ip) before trigger of spasms with NMDA (postnatal day 15) 50 Spasm count Spasm 0 Treatment with ANAVEX 2-73 significantly reduced the number of spasms by 55% compared to vehicle 12 Fragile X Syndrome § Rare neurodevelopmental disorder § MutaCon, CGG trinucleoCde repeats (typically >200), in the FMR1 gene cause Fragile X syndrome § AffecCng approximately 1 in 4,000 males and 1 in 6,000 females Symptoms include: § Seizures (13-44% of paCent populaCon)1 § Comorbidity with epilepsy has been found to be associated with polymorphisms in the brain-derived neurotrophic factor (BDNF) gene2 § AtenCon Problems § Anxiety § Developmental Delay § Hyperacvity 1 Berry-Kravis E. Dev Med Child Neurol. 2002 Nov;44(11):724-8 13 2 Louhivuori V et al. Epilepsy Res. 2009 Jul;85(1):114-7 BDNF Levels in Hippocampus as Biomarker § BDNF under-expression has been observed in many neurodevelopmental as well as neurodegeneraCve pathologies. BDNF signaling promotes maturaCon of both excitatory and inhibitory synapses#, and normalizaCon of BDNF expression could be beneficial in both neurodevelopmental and neurodegenerave disorders § ANAVEX 2-73 (1 mg/kg ip dosed twice daily for 14 days) was evaluated for its effect on potenCal biomarkers in 2-month old Fragile X mental retardaCon 1 knockout (Fmr1 KO) mice − BDNF protein levels in the hippocampus were measured by ELISA § The study was sponsored by FRAXA and performed by Fraunhofer Chile Research, SanCago, Chile # Castrén ML & Castrén E. Neuropharmacology. 2014 Jan;76 Pt C:729-36 14 ANAVEX 2-73 Normalizes Hippocampal BDNF Expression p<0.05 § AdministraCon of ANAVEX 2-73 in the Fragile X Fmr1 KO mouse significantly restores hippocampal BDNF expression to the same levels observed in vehicle-treated wild- type mice (p<0.05, KO vehicle vs. KO ANAVEX 2-73) 15 Ret Syndrome § Rare, non-inherited genec postnatal progressive neurodevelopmental disorder § 95% of cases due to mutaCons in MECP2 Gene (X Chromosome) § Occurs almost exclusively in girls § Affects 1 in 10,000 to 15,000 Symptoms include: § Seizures (86% in the adult paCent populaCon) § Anxiety § CogniCve impairment § Apraxia (motor speech disorder) § Loss of purposeful hand movement, stereotypic hand movement § Balance and coordinaCon issues, decrease or loss of ability to walk § Respiratory dysfuncCons "Re` Syndrome Fact Sheet", NINDS, PublicaHon date November 2009.NIH PublicaHon No. 09-4863 Image Source: Re`Syndrome.org, paent Jilly 16 Ret Syndrome Data: OptokineCc Response (OKR) § ANAXEX 2-73 (30 mg/kg po dosed daily for 4 weeks) was evaluated in the MECP2 Ret syndrome model using 7 months old mice, an age in which advanced pathology is evident § The mice were tested for changes in optokinec (automaCc visual) # response § RaConale This method depends on the automaCc visual response of head-tracking to a moving verCcal stripe patern presented on a rotaCng drum to an animal placed at its center # The study was sponsored by Re`syndrome.org and performed by PsychoGenics, Inc. 17 ANAVEX 2-73 Rescues Optokinec Response § Vehicle-treated HET mice showed fewer responses than vehicle-treated WT mice at 1.5 RPM, 2.8 RPM as well as total of both drum speeds § HET mice treated with AV2-73 (30 mg/kg po) showed an increased response compared to the vehicle-treated HET mice at 1.5 RPM as well as total of both drum speeds #p<0.05 compared to WT vehicle group *p<0.05 compared to HET vehicle group 18 ANAVEX 2-73 Demonstrated a Trend related to the amount of Apneas § Apneas were defined as expiratory Cme greater than 1 second § A trend was observed in MECP2 mice treated with ANAVEX 2-73 – that is, a reducCon in apnea counts to levels comparable to those observed in wild-type animals 19 The Effects of ANAVEX 2-73 in Neurodevelopmental Disorders § Previous results have demonstrated that administraCon of ANAVEX 2-73 results in both significant and dose related improvements in an array of movement paradigms in the MECP2 HET Ret syndrome disease model and in the Fragile X Fmr1 KO disease model § The new results further suggest that ANAVEX 2-73 could be of potenCal value for the treatment of various neurodevelopmental diseases including Ret syndrome, Fragile X and Angelman syndrome Coupled with posiCve human safety and clinical cogniCon data, as well as preclinical an-seizure and an-anxiety data, ANAVEX 2-73 will be tested as a potenCal drug candidate in Ret syndrome 20 ANAVEX™ 2-73 Clinical Trial Strategy ANAVEX™2-73-001 Study: • Phase 1 (oral) • Single Ascending Dose (SAD) Completed • Healthy subjects ANAVEX™2-73-002 Study#: • Phase 2a (iv/oral) • Mild-to-moderate AD paCents More • AdapCve trial with PopulaCon PK PART A: Completed “informaCve” • PART B: Completed trial Bioavailability, dose finding (PART A), and exploratory efficacy with 52 week open-label PopulaCon PK analysis: Upcoming readout extension (PART B) ANAVEX™2-73-003 Study: • 104-week extension study aer PART B ANAVEX™2-73-101 Study: ANAVEX™2-73-004 Study: • Phase 2 (oral) • Phase 2/3 (oral) • Ret syndrome paCents • Mild-to-moderate AD paCents Preparaon underway • Double-blind, placebo controlled study • Double-blind, placebo controlled study • <3 month efficacy • 6/12 month efficacy # ClinicalTrials.gov IdenHfier: NCT02244541 21 ANAVEX 2-73 Phase 2a: 57 Week Safety Profile (MTD Study) § 32 mild-to-moderate AD paCents (baseline MMSE: 16-28) § The most common AEs at highest doses were mild dizziness followed by mild headache § Consistent with Blood Brain Barrier (BBB) penetraCon § 98% of all AEs were mild or moderate and reversible with 76% being Grade 1 § 2% were Grade 3 § There were no Grade 4 and 5 events § AE profile similar to that of healthy volunteer Phase 1 data § No differences in blood pressure or resCng heart rate § Clinical laboratory parameters, vital signs, and 12-lead ECG did not show any clinically relevant or dose-dependent changes Voges et al., presented at CNS Summit 2014; Macfarlane, presented at CTAD 2016 22 2017 Clinical funding: 23 Contact Us Corporate Office: Shareholder & Media Relaons: Anavex™ Life Sciences Corp. Toll-free: 1-866-505-2895 51 West 52nd Street, 7th floor Outside North America: New York, NY 10019 + 1 (917) 733-9297 Email: [email protected] (212) 332 4449 www.anavex.com NASDAQ: AVXL ANAVEX is a trademark of Anavex Life Sciences Corp.
Load more

Recommended publications
  • Special Report
    RARERARE PEDIATRICPEDIATRIC DISEASESDISEASES SPECIAL REPORT SELECTED ARTICLES Rare Diseases Pose a Pressing Challenge: Are State-by-State Differences in Newborn 02 09 Get the Diagnostic Work Done Swiftly Screening an Impediment or Asset? Rare Epileptic Encephalopathies: Neurodevelopmental Concerns May Emerge 05 21 Update on Directions in Treatment Later in Zika-exposed Infants EDITOR’S NOTE housands of rare diseases have been identified, but only T 35 core conditions are on the federal Recommended Uniform Screening Panel (RUSP). But the majority of states don’t screen for all 35 conditions. Read on to learn about the pros and cons of state-by- state differences in newborn screening for rare disorders. But newborn Catherine Cooper screening is not the only way to learn about a child’s rare disease. There Nellist is genetic screening, and now it is more widely available than ever. But how to make sense of that information? Certified genetic counselors will help, but health care providers need education about what to do when a rare disease is diagnosed. In this Rare Pediatric Diseases Special Report, there are resources for you as health care providers and for your patients provided by the National Institutes of Health and by the National Organization for Rare Disorders. Explore a synopsis of existing and emerging treatments of three rare epileptic encephalopathies that occur in infancy and early childhood— West syndrome, Lennox-Gastaut syndrome, and Dravet syndrome. Learn about important advancements in the treatment of three rare pediatric neuromuscular disorders—spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and X-linked myotubular myopathy (XLMTM)—and how improved quality of life and survival will challenge current EDITOR systems of transition care.
    [Show full text]
  • Looks Like Angelman Syndrome but Isn’T – What Is in the Differential?
    R.C.P.U. NEWSLETTER Editor: Heather J. Stalker, M.Sc. Director: Roberto T. Zori, M.D. R.C. Philips Research and Education Unit Vol. XXII No. 1 A statewide commitment to the problems of mental retardation January 2011 R.C. Philips Unit ♦ Division of Pediatric Genetics, Box 100296 ♦ Gainesville, FL 32610 ♦ (352)294-5050 E Mail: [email protected]; [email protected] Website: http://www.peds.ufl.edu/divisions/genetics/newsletters.htm Looks like Angelman syndrome but isn’t – What is in the differential? Charles A. Williams, MD Division of Pediatric Genetics & Metabolism University of Florida Angelman syndrome Differential Diagnosis of Angelman syndrome (AS) Angelman syndrome is a neurobehavioral disorder characterized by Individuals with AS-like features often present with psychomotor delay and/or developmental delay, progressive microcephaly, ataxic gait, absence of seizures and the differential diagnosis can be broad, encompassing such speech, seizures and a characteristic behavioral phenotype which includes non-specific entities as cerebral palsy, static encephalopathy, autism and happy demeanor and spontaneous bouts of laughter. AS was originally mitochondrial encephalomyopathy. Tremulousness and jerky limb called the “Happy Puppet Syndrome” in its description by Harry Angelman in movements, seen in most individuals with AS may help distinguish it from 1965 in an attempt to describe the upheld hands, clumsy gait and happy these conditions (see table below for other helpful distinguishing features). demeanor of individuals with this condition. The incidence is estimated to be Specific syndromes that mimic AS are reviewed below. Table 1 provides a between 1 in 15,000 and 1 in 20,000 live births.
    [Show full text]
  • Angelman Syndrome Clinical Management Guidelines
    Management of Angelman Syndrome A Clinical Guideline Angelman Syndrome Guideline Development Group Angelman Syndrome Clinical Management Guidelines Contents Introduction 3 … to Angelman Syndrome 3 … to the Angelman Syndrome Guidelines Development project 3 … to the Angelman Syndrome Clinical Management Guidelines 3 Diagnosis of Angelman Syndrome 4 … Clinical Diagnosis 4 … Genetic Investigation 5 Recommendations for the Management of Angelman Syndrome 6 … Feeding and Diet 6 … Speech and Communication 12 … Development 7 … Dental and Drooling 13 … Seizures and CNS 8 … General health and Anaesthesia 14 … Sleep 9 … Scoliosis and Skeletal 15 … Vision and Hearing 10 … Sexual health and Puberty 16 … Behaviour 11 … Alternative therapies 17 Information for Parents 18 Bibliography 19 APPENDIX: Genetic Mechanisms in Angelman Syndrome 24 Acknowledgements 25 Angelman Syndrome Clinical Management Guidelines 2 Introduction... … to Angelman Syndrome (AS) Angelman syndrome is a neurodevelopmental disorder that occurs in 1 in 20-40,000 births. It is characterised by severe learning difficulties, ataxia, a seizure disorder with a characteristic EEG, subtle dysmorphic facial features, and a happy, sociable disposition. Most children present with delay in developmental milestones and slowing of head growth during the first year of life. In the majority of cases speech does not develop. Patients with AS have a characteristic behavioural phenotype with jerky movements, frequent and sometimes inappropriate laughter, a love of water, and sleep disorder. The facial features are subtle and include a wide, smiling mouth, prominent chin, and deep set eyes. It is caused by a variety of genetic abnormalities involving the chromosome 15q11-13 region, which is subject to genomic imprinting. These include maternal deletion, paternal uniparental disomy, imprinting defects, and point mutations or small deletions within the UBE3A gene, which lies within this region (see Appendix: Genetic Mechanisms in AS, p.
    [Show full text]
  • HIGH RISK 1P36 This Pregnancy Is Classified As HIGH RISK by This Screen for a Deletion at 1P36, Which Is Associated with 1P36 Deletion Syndrome
    Patient Report |FINAL Client: Example Client ABC123 Patient: Patient, Example 123 Test Drive Salt Lake City, UT 84108 DOB 4/3/1982 UNITED STATES Gender: Female Patient Identifiers: 01234567890ABCD, 012345 Physician: Doctor, Example Visit Number (FIN): 01234567890ABCD Collection Date: 01/01/2017 12:34 Non-Invasive Prenatal Testing for Fetal Aneuploidy with Microdeletions ARUP test code 2010232 Result Summary HIGH RISK 1p36 This pregnancy is classified as HIGH RISK by this screen for a deletion at 1p36, which is associated with 1p36 deletion syndrome. This result should be confirmed by a diagnostic test. Dependent on fetal fraction, 7 to 17% of pregnancies classified as HIGH RISK are found to have 1p36 deletion syndrome. TEST INFORMATION: Non-Invasive Prenatal Testing for Fetal Aneuploidy (Powered by Constellation) with or without Microdeletions METHODOLOGY: DNA isolated from the maternal blood, which contains placental DNA, is amplified at 13,300+ loci using a targeted PCR assay and sequenced using a high-throughput sequencer. Sequence data are analyzed using Natera's Constellation software to estimate the fetal copy number and identify whole chromosome abnormalities for chromosomes 13, 18, 21, X, and Y as well as fetal sex. Barring QC failures and fetal fractions below the performance limits of the algorithm, the minimum confidence threshold is 0.98 for a high risk call. For both low risk and high risk calls, the majority of specimens will have a confidence of >0.99 across all regions tested. If a sample fails to meet the quality threshold, no result will be reported for one or more chromosomes. Microdeletions: An additional 6,600+ loci are amplified to estimate the fetal copy numbers of chromosomal regions attributed to 22q11.2, Prader-Willi, Angelman, Cri-du-chat, and 1p36 deletion syndromes.
    [Show full text]
  • Autism in Genetic Syndromes: Implications for Assessment and Intervention
    © © Cerebra Cerebra 2012 2009 Autism in genetic syndromes: Implications for assessment and intervention. Introduction Dr. Jo Moss and Prof. Chris Oliver This briefing has been prepared to help parents and carers of children with genetic syndromes understand how and why autism spectrum disorder or Cerebra Centre for related characteristics might be seen in children with genetic syndromes and Neurodevelopmental what this might mean for assessment and intervention. This briefing provides Disorders (CNDD) a summary of information presented in a peer reviewed scientific article University of Birmingham published in 20091 and an academic book chapter published in 2011.2 1. What is Autism Spectrum Disorder? Autism spectrum disorder (ASD) is a developmental disability that occurs in up to 1% of children and adults in the general population3 and up to 40% of individuals within the learning disability population.4 ASD is diagnosed on the basis of observable impairments and behaviours in three core areas (also known as the triad of impairments). These are: 1. impairments in communication and language, 2. impairments in social interaction and social relatedness and, 3. the presence of repetitive behaviours and restricted interests. In children with ASD, difficulties in these three areas are typically evident before the age of three years. ASD is a spectrum condition, which means that while all people with ASD share certain difficulties, there is a great deal of variability in the way in which these difficulties are seen and in their severity. 2. What is the cause of Autism Spectrum Disorder? The specific causes of ASD remain unknown but most studies indicate a biological or genetic cause.5 A high level of heritability (passing within families) of ASD characteristics in families and siblings of affected individuals has been reported.6 However, this is not always the case and there are many individuals with ASD in which there are no familial links to the condition.7 Registered Charity no.
    [Show full text]
  • Chromosomal Disorders
    Understanding Genetic Tests and How They Are Used David Flannery,MD Medical Director American College of Medical Genetics and Genomics Starting Points • Genes are made of DNA and are carried on chromosomes • Genetic disorders are the result of alteration of genetic material • These changes may or may not be inherited Objectives • To explain what variety of genetic tests are now available • What these tests entail • What the different tests can detect • How to decide which test(s) is appropriate for a given clinical situation Types of Genetic Tests . Cytogenetic . (Chromosomes) . DNA . Metabolic . (Biochemical) Chromosome Test (Karyotype) How a Chromosome test is Performed Medicaldictionary.com Use of Karyotype http://medgen.genetics.utah.e du/photographs/diseases/high /peri001.jpg Karyotype Detects Various Chromosome Abnormalities • Aneuploidy- to many or to few chromosomes – Trisomy, Monosomy, etc. • Deletions – missing part of a chromosome – Partial monosomy • Duplications – extra parts of chromosomes – Partial trisomy • Translocations – Balanced or unbalanced Karyotyping has its Limits • Many deletions or duplications that are clinically significant are not visible on high-resolution karyotyping • These are called “microdeletions” or “microduplications” Microdeletions or microduplications are detected by FISH test • Fluorescence In situ Hybridization FISH fluorescent in situ hybridization: (FISH) A technique used to identify the presence of specific chromosomes or chromosomal regions through hybridization (attachment) of fluorescently-labeled DNA probes to denatured chromosomal DNA. Step 1. Preparation of probe. A probe is a fluorescently-labeled segment of DNA comlementary to a chromosomal region of interest. Step 2. Hybridization. Denatured chromosomes fixed on a microscope slide are exposed to the fluorescently-labeled probe. Hybridization (attachment) occurs between the probe and complementary (i.e., matching) chromosomal DNA.
    [Show full text]
  • ORD Resources Report
    Resources and their URL's 12/1/2013 Resource Name: Resource URL: 1 in 9: The Long Island Breast Cancer Action Coalition http://www.1in9.org 11q Research and Resource Group http://www.11qusa.org 1p36 Deletion Support & Awareness http://www.1p36dsa.org 22q11 Ireland http://www.22q11ireland.org 22qcentral.org http://22qcentral.org 2q23.org http://2q23.org/ 4p- Support Group http://www.4p-supportgroup.org/ 4th Angel Mentoring Program http://www.4thangel.org 5p- Society http://www.fivepminus.org A Foundation Building Strength http://www.buildingstrength.org A National Support group for Arthrogryposis Multiplex http://www.avenuesforamc.com Congenita (AVENUES) A Place to Remember http://www.aplacetoremember.com/ Aarons Ohtahara http://www.ohtahara.org/ About Special Kids http://www.aboutspecialkids.org/ AboutFace International http://aboutface.ca/ AboutFace USA http://www.aboutfaceusa.org Accelerate Brain Cancer Cure http://www.abc2.org Accelerated Cure Project for Multiple Sclerosis http://www.acceleratedcure.org Accord Alliance http://www.accordalliance.org/ Achalasia 101 http://achalasia.us/ Acid Maltase Deficiency Association (AMDA) http://www.amda-pompe.org Acoustic Neuroma Association http://anausa.org/ Addison's Disease Self Help Group http://www.addisons.org.uk/ Adenoid Cystic Carcinoma Organization International http://www.accoi.org/ Adenoid Cystic Carcinoma Research Foundation http://www.accrf.org/ Advocacy for Neuroacanthocytosis Patients http://www.naadvocacy.org Advocacy for Patients with Chronic Illness, Inc. http://www.advocacyforpatients.org
    [Show full text]
  • Prader Willi and Angelman Syndrome PCR Tests
    Prader Willi and Angelman Syndrome PCR Tests The UNC Hospitals Molecular Genetics Laboratory offers a PCR test for defects of the gene region on chromosome 15 associated with Prader Willi and Angelman syndromes. Molecular basis of the diseases: Prader-Willi and Angelman syndromes involve an imprinted region on chromosome 15 where genes are differentially methylated and therefore differentially expressed depending on the parental origin of the chromosome. Besides an imprinting error, gene deletion or uniparental disomy are other mechanisms for loss of gene expression. Prader-Willi syndrome results from absence (or lack of expression) of genes that are normally expressed from the paternal allele, whereas Angelman syndrome is caused by absence (or lack of expression) of genes normally expressed from the maternal allele. These are referred to as “reciprocal syndromes”. Prader-Willi syndrome (PWS) is a common syndromal cause of obesity. Incidence is estimated to be 1:20,000. In infancy PWS manifests with profound hypotonia, mild prenatal growth retardation, poor feeding and failure to thrive. Starting at about 12 to 18 months of age, patients exhibit uncontrolled overeating, and obesity becomes a major diagnostic feature and a major health problem. Other common clinical features include short stature, mild mental retardation, gross motor delay, characteristic facial features and behavioral problems. Deletions in the paternally inherited chromosome 15q11q13 account for approximately 70% of PWS cases. Maternal uniparental disomy (UPD) and imprinting defects in the 15q region are other causes of PWS that are detectable by the new PCR assay. Angelman syndrome (AS) is characterized by severe motor and intellectual retardation, ataxia, absence of speech, hyperactivity, hypotonia and frequent smiling with episodes of unprovoked laughter.
    [Show full text]
  • Neurological Syndromes
    Neurological Syndromes J. Gordon Millichap Neurological Syndromes A Clinical Guide to Symptoms and Diagnosis J. Gordon Millichap, MD., FRCP Professor Emeritus of Pediatrics and Neurology Northwestern University Feinberg School of Medicine Chicago, IL, USA Pediatric Neurologist Ann & Robert H. Lurie Children’s Hospital of Chicago Chicago , IL , USA ISBN 978-1-4614-7785-3 ISBN 978-1-4614-7786-0 (eBook) DOI 10.1007/978-1-4614-7786-0 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2013943276 © Springer Science+Business Media New York 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • Angelman Syndrome
    Angelman syndrome Description Angelman syndrome is a complex genetic disorder that primarily affects the nervous system. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia). Most affected children also have recurrent seizures (epilepsy) and a small head size (microcephaly). Delayed development becomes noticeable by the age of 6 to 12 months, and other common signs and symptoms usually appear in early childhood. Children with Angelman syndrome typically have a happy, excitable demeanor with frequent smiling, laughter, and hand-flapping movements. Hyperactivity, a short attention span, and a fascination with water are common. Most affected children also have difficulty sleeping and need less sleep than usual. With age, people with Angelman syndrome become less excitable, and the sleeping problems tend to improve. However, affected individuals continue to have intellectual disability, severe speech impairment, and seizures throughout their lives. Adults with Angelman syndrome have distinctive facial features that may be described as "coarse." Other common features include unusually fair skin with light-colored hair and an abnormal side-to-side curvature of the spine (scoliosis). The life expectancy of people with this condition appears to be nearly normal. Frequency Angelman syndrome affects an estimated 1 in 12,000 to 20,000 people. Causes Many of the characteristic features of Angelman syndrome result from the loss of function of a gene called UBE3A. People normally inherit one copy of the UBE3A gene from each parent. Both copies of this gene are turned on (active) in many of the body's tissues. In certain areas of the brain, however, only the copy inherited from a person's mother (the maternal copy) is active.
    [Show full text]
  • Aarskog Syndrome Parents Support Group
    Aarskog Syndrome Parents Support Group http://www.familyvillage.wisc.edu/lib_aars.htm AboutFace USA (For people with facial differences) http://www.aboutfaceusa.org AboutFace International http://www.aboutfaceinternational.org ; http://aboutface.ca/ Abetalipoproteinemia (International) http://www.abetalipoproteinemia.org/ Accord Alliance (Disorders of Sexual Development) http://www.accordalliance.org/ Achalasia Support Groups http://achalasia.us/Support_Groups.html Acid Maltase Deficiency Association http://www.amda-pompe.org/ Acoustic Neuroma Association http://anausa.org/ Addison’s Disease Self Help Group UK http://www.addisons.org.uk/ Adinoid Cystic Carcinoma Organization International http://www.accoi.org/ Adinoid Cystic Carcinoma Research Foundation http://www.accrf.org/ Advocacy for Neuroacanthocytosis Patients http://www.naadvocacy.org/ AIS-DSD Support Group USA (Disorders of Sex Development) http://www.aisdsd.org Ais (Androgen Insensitivity Syndrome) Support Group http://www.aissg.org (UK based) AKU (Alkaptonuria) Society http://www.alkaptonuria.info/ Alagille Syndrome Alliance http://www.alagille.org/ ALS Association (Amyotrophic Lateral Sclerosis) http://www.alsa.org Alopecia Support Group (ASG) http://www.alopeciasupport.org/ Alpha-1 Association (Alpha-1 Antitrypsin Deficiency) http://www.alpha1.org/ Alpha-1 Canada http://www.alpha1canada.ca/ Alpha-1 Foundation http://www.alpha-1foundation.org/ Alport Syndrome Foundation http://www.alportsyndrome.org Alstrom Syndrome International http://www.alstrom.org/ Alternating Hemiplegia
    [Show full text]
  • Informed Consent for Prader-Willi Angelman Syndrome By
    Laboratory of Personalized Genomic Medicine 630 West 168th Street Department of Pathology and Cell Biology P&S 11th Floor, Room 453 New York, NY 10032 Tel: 212‐305‐9706 Fax: 212‐342‐0420 Informed Consent for Prader‐Willi Angelman Syndrome by PCR Please read the following form carefully and discuss with your ordering physician/genetic counselor before signing consent. 1. This is a genetic (DNA‐based) test that detects the presence of maternally and/or paternally inherited region of chromosome 15, using a PCR‐based assay. 2. The purpose of this analysis is to test for Prader‐Willi and Angelman syndromes. 2a. You (or the person for whom you are signing) may want genetic counseling before signing consent. 3. This is a test for genetic susceptibility (“genetic predisposition”). If the test is positive, you may wish to have further independent testing, consult your physician or have genetic counseling. 4. The condition(s) being tested for are Prader‐Willi and Angelman syndromes, two different disorders affecting development and behavior. 5. When the paternal copy is absent, there is an approximately 99% chance of manifesting Prader‐Willi Syndrome. When the maternal copy is absent, there is an approximately 99% chance of manifesting Angelman Syndrome. When a normal methylation pattern is present, the risk of having Angelman Syndrome or Prader‐Willi Syndrome will depend upon clinical manifestations. Up to 16% of Angelman Syndrome patients, and up to 5% or Prader‐Willi Syndrome patients will have normal results with this test. 6. The results of the above test become a part of the patient’s medical record, and may be made available to individuals/organizations with legal access to the patient’s medical record, on a strict “need‐to‐know” basis, including but not limited to the physicians and nursing staff directly involved in the patient’s care, the patient’s current and future insurance carriers, and other specifically authorized by the patient/authorized representative to gain access to the patient’s medical records.
    [Show full text]